Prevalence and biochemical profile of adynamic bone disease in a hemodialysis population
Keywords:adynamic bone disease, hemodialysis, mineral bone disease
Introduction and Aim: The number of patients suffering from end stage renal disease (ESRD) requiring dialysis has increased worldwide. Mineral bone disorders (MBD) commonly occur in ESRD patients. MBD is classified into high turnover bone disease and low turnover bone disease. Biochemical parameters play a key role in classifying MBD. Data on adynamic bone disease (ABD) in hemodialysis (HD) patients is sparse. The aim is to study the prevalence and biochemical profile of ABD in hemodialysis patients.
Materials and Methods: This study was done as a cross sectional study in HD patients of a tertiary care hospital in South India. Baseline demographic data of the study population was collected. Biochemical data such as serum creatinine, blood urea nitrogen (BUN), bone markers for the diagnosis of CKD-MBD including serum calcium, phosphorus, alkaline phosphatase (ALP) and intact parathyroid hormone (iPTH) were collected. Based on the biochemical values, patients who had parameters suggestive of ABD were grouped as a separate cohort. Prevalence of ABD was calculated. Descriptive analysis of ABD cohort was done. Correlation of various bone markers with iPTH was carried out.
Results: The study population (n=150) included 96 male (64%) and 54 female (36%) HD patients. The mean age of the study population is 54.54±14.81 years. 32.7% (n=49) of our study population had ABD. Serum calcium was found to be significantly higher in the ABD group. ALP and phosphorus were significantly lower in the ABD group.
Conclusion: The prevalence of ABD in our HD population was 32.7%. The prevalence of ABD was the same among males and females. There was significant correlation of iPTH levels with ALP, calcium, and phosphorus levels.
El Nahas, M., Khwaja, A. Epidemiology, Natural History, and Pathophysiology of Chronic Kidney Disease; In Comprehensive clinical nephrology / [edited by] Richard J. Johnson, John Feehally, Jürgen Floege (Fifth edition)
Martin, K. J., Floege, J., Ketteler, M. Bone and Mineral Metabolism in Chronic Kidney Disease; In Comprehensive clinical nephrology / [edited by] Richard J. Johnson, John Feehally, Jürgen Floege (Fifth edition)
Massy, Z., Drueke, T. Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease. J Nephrol. 2017 Oct; 30(5):629-634.
Sharma, S., Gupta, A. Adynamic bone disease: Revisited. Nefrologia (Engl Ed). 2021 Mar 8; S0211-6995(21)00025-4.
Sethi, S., Sethi, N., Sandhu, J. S., Makkar, V., Kaur, S., Sohal, P. M., et al., Changing Spectrum of Mineral Bone Disorder in Chronic kidney disease stage 3 to 5 D and Its Associated Factors, A Prospective Cross-Sectional Study from Tertiary Care Hospital in Northern India. Iran J Kidney Dis. 2021 May; 15(3):199-205.
GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020 Feb 29;395(10225):709-733.
Jesus, N.M., Souza, G. F., Mendes-Rodrigues, C., Almeida Neto, O. P., Rodrigues, D. D. M., Cunha, C. M. Quality of life of individuals with chronic kidney disease on dialysis. J Bras Nefrol. 2019 Jul-Sep;41(3):364-374.
Tentori, F., Blayney, M. J., Albert, J. M., Gillespie, B. W., Kerr, P. G., Bommer, J., et al., Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008 Sep;52(3):519-530.
Reddy, Y. N., Abraham, G., Reddy, Y. N., Nagarajan, P., Matthew, M., Jayaseelan, T., et al., Mineral bone disease in maintenance hemodialysis patients: Association with morbidity and mortality. Indian J Nephrol. 2014 Sep;24(5):302-307.
Slinin, Y., Foley, R. N., Collins, A. J. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol. 2005 Jun; 16(6):1788-1793.
Sista, S. K., Arum, S. M. Management of adynamic bone disease in chronic kidney disease: A brief review. J Clin Transl Endocrinol. 2016 Jul 25; 5:32-35.
Ott, S. M., Malluche, H.H., Jorgetti, V., Elder, G. J. Importance of bone turnover for therapeutic decisions in patients with CKD-MBD. Kidney Int. 2021 Sep;100(3):502-505.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011). 2017 July;7(1):1-59.
Abdu, A., Abdu, A., Arogundade, F. A. Prevalence and pattern of chronic kidney disease-mineral bone disorders among hemodialysis patients in kano, northwest nigeria. Ann Afr Med. 2019 Oct-Dec; 18(4):191-195.
Vikrant, S., Parashar, A. Prevalence and severity of disordered mineral metabolism in patients with chronic kidney disease: A study from a tertiary care hospital in India. Indian J Endocrinol Metab. 2016 Jul-Aug;20(4):460-467.
Abrita, R. R., Pereira, B. D. S., Fernandes, N. D. S., Abrita, R., Huaira, R. M. N. H., Bastos, M. G., et al., Evaluation of prevalence, biochemical profile, and drugs associated with chronic kidney disease-mineral and bone disorder in 11 dialysis centers. J Bras Nefrol. 2018 Jan-Mar;40(1):26-34.
Valson, A. T., Sundaram, M., David, V. G., Deborah, M. N., Varughese, S., Basu, G., et al., Profile of incident chronic kidney disease related-mineral bone disorders in chronic kidney disease Stage 4 and 5: A hospital based cross-sectional survey. Indian J Nephrol. 2014 Mar;24(2):97-107.
Ghosh, B., Brojen, T., Banerjee, S., Singh, N., Singh, S., Sharma, O. P., et al., The high prevalence of chronic kidney disease-mineral bone disorders: A hospital-based cross-sectional study. Indian J Nephrol. 2012 July;22(4):285-291.
Ketteler, M., Block, G.A., Evenepoel, P., Fukagawa, M., Herzog, C.A., McCann, L., et al., Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int. 2017 July;92(1):26-36.
How to Cite
Copyright (c) 2023 Biomedicine
This work is licensed under a Creative Commons Attribution 4.0 International License.